SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma trades higher on the bourses

03 Oct 2011 Evaluate

Ajanta Pharma is currently trading at Rs. 298.05, up by 1.20 points or 0.40% from its previous closing of Rs. 296.85 on the BSE.

The scrip opened at Rs. 296.00 and has touched a high and low of Rs. 302.00 and Rs. 289.10 respectively. So far 3,883 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 368.00 on 22-Jul-2011 and a 52 week low of Rs. 172.00 on 18-Jan-2011.

Last one week high and low of the scrip stood at Rs. 330.00 and Rs. 289.10 respectively. The current market cap of the company is Rs. 348.00 crore.

The promoters holding in the company stood at 66.82% while Institutions and Non-Institutions held 0.32% and 32.86% respectively.

Credit rating agency, CARE has reaffirmed the assigned ‘A+/A1’ rating to long-term/short-term bank facilities of Ajanta Pharma for Rs 120.00 crore. The agency has also reaffirmed the assigned ‘A1’ rating to the short-term bank facilities of the company for Rs 35.00 crore.

Further, the agency has also reaffirmed the assigned ‘A+’ rating to long-term loans of the company for Rs 67.87 crore.

The ability of the company to achieve the projected sales and profitability remain the key rating sensitivities. However, the ratings continue to be constrained by the long working capital cycle, volatile nature of raw material prices and increasing competition in the domestic formulation market from multinationals and Indian drug manufacturers.

Ajanta Pharma is engaged in manufacturing and marketing of pharmaceutical formulations. The company’s product portfolio includes around 200 active products including line extensions catering to various therapeutic segments including Cardiovascular Diseases (CVD), Dermatology, Pediatrics, Ophthalmology, Nephrology, Orthopaedic, amongst others.

Ajanta Pharma Share Price

3080.20 -13.05 (-0.42%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×